Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16378426 | 0.88 | BACE1 (0.34) | BACE1BACE2 | |
| SCHEMBL9923752 | 0.88 | BACE1 (0.34) | BACE1BACE2 | |
| SCHEMBL2594 | 0.86 | BACE1 (0.36) | BACE1BACE2CTSDALDH1A1HPGD | |
| SCHEMBL2595 | 0.86 | BACE1 (0.36) | BACE1BACE2CTSDALDH1A1HPGD | |
| SCHEMBL19263475 | 0.84 | BACE1 (0.34) | BACE1USP30BACE2CTSD | |
| SCHEMBL10328591 | 0.83 | BACE1 (0.37) | BACE1USP30BACE2CTSD | |
| SCHEMBL12721450 | 0.83 | BACE1 (0.37) | BACE1USP30BACE2CTSD | |
| SCHEMBL2172997 | 0.82 | GRM5 (0.35) | BACE1USP30CCNB2CDK1CCNB1 | |
| SCHEMBL2173003 | 0.82 | GRM5 (0.35) | BACE1USP30CCNB2CDK1CCNB1 | |
| SCHEMBL9923747 | 0.82 | GRM5 (0.35) | BACE1USP30CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557826-B2 | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120148603-A1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148603-A1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, BACE2 | BACE1 1/4885CYP1A2 1520/4885CYP3A4 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.